In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events
PMID: 37399559
Source: Ann Intern Med
Publication date:
2025-07-24
Year:
2023
Abstract
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401:1159-1171. 36871574.